Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) results from the expansion of a glutamine repeat near the N-terminus of huntingtin (htt). At post-mortem, neurons in the central nervous system of patients have been found to accumulate N-terminal fragments of mutant htt in nuclear and cytoplasmic inclusions. This pathology has been reproduced in transgenic mice expressing the first 171 amino acids of htt with 82 glutamines along with losses of motoric function, hypoactivity and abbreviated life-span. The relative contributions of nuclear versus cytoplasmic mutant htt to the pathogenesis of disease have not been clarified. To examine whether pathogenic processes in the nucleus disproportionately contribute to disease features in vivo, we fused a nuclear localization signal (NLS) derived from atrophin-1 to the N-terminus of an N171-82Q construct. Two lines of mice (lines 8A and 61) that were identified expressed NLS-N171-82Q at comparable levels and developed phenotypes identical to our previously described HD-N171-82Q mice. Western blot and immunohistochemical analyses revealed that NLS-N171-82Q fragments accumulate in nuclear, but not cytoplasmic, compartments. These data suggest that disruption of nuclear processes may account for many of the disease phenotypes displayed in the mouse models generated by expressing mutant N-terminal fragments of htt.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228 · cited 1×
“However, in work focusing on the CBP pathway, several studies have demonstrated that restoring this pathway by augmenting CBP function through transgene expression (24) or by inhibiting histone deacetylases pharmacologically (CBP is a histone acetylase) ( 50 ,63) diminishes the toxicity of mutant htt.”
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914 · cited 3×
“We used a monoclonal antibody (mEM48) that is similar to the originally described rabbit antiserum rEM48, reported to demonstrate preference to detect cytoplasmic aggregates (11,18).”
Boutell, J. M., Thomas, P., Neal, J. W., Weston, V. J., Duce, J., Harper, P. S., & Lesley Jones, A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.9.1647 · Cited by 310 · cited 1×
“Several studies have demonstrated that mutant htt, or proteins with expanded glutamine tracts, can interact with transcription factors, including CREB-binding protein (24,49,54), p53 (49), Sp 1 (45,55), TAFII130 (45,56,57), TATA-binding protein (56), REST/NRSF (53,58), NCoR (59,60), NF-kB/Rel/dorsal family member (61)…”
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses
Sipione, S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.17.1953 · Cited by 209
Cited by
p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease
Bae, B.-I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.005 · Cited by 485
Self-citationHuntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Mutant Huntingtin Disrupts the Nuclear Pore Complex
Grima, J. C., Daigle, J. G., Arbez, N., Cunningham, K. C., Zhang, K., Ochaba, J., Geater, C., Morozko, E., Stocksdale, J., Glatzer, J. C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.03.023 · Cited by 356
Self-citationThe mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms
Kang, I., Chu, C. T., & Kaufman, B. A. (2018) · FEBS Letters · doi:10.1002/1873-3468.12989 · Cited by 324
Iwata, A., Christianson, J. C., Bucci, M., Ellerby, L. M., Nukina, N., Forno, L. S., & Kopito, R. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505801102 · Cited by 318
Metadata
- Authors
- Schilling, G., Savonenko, A. V., Klevytska, A., Morton, J. L., Tucker, S. M., Poirier, M., Gale, A., Chan, N., Gonzales, V., Slunt, H. H., Coonfield, M. L., Jenkins, N. A., Copeland, N. G., Ross, C. A., & Borchelt, D. R.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-09
- Volume
- 13
- Issue
- 15
- Pages
- 1599-1610
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2135835736
- Cited by
- 104
- References
- 5
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. https://app.cochat.ai/papers/10.1093/hmg/ddh175
- The paper
- Schilling, G., Savonenko, A. V., Klevytska, A., Morton, J. L., Tucker, S. M., Poirier, M., Gale, A., Chan, N., Gonzales, V., Slunt, H. H., Coonfield, M. L., Jenkins, N. A., Copeland, N. G., Ross, C. A., & Borchelt, D. R. (2004). Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddh175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.